- Home
- RCON vs CVKD Comparison
RCON vs CVKD Comparison
Compare RCON & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCON
- CVKD
- Stock Information
- Founded
- RCON 2007
- CVKD 2022
- Country
- RCON China
- CVKD United States
- Employees
- RCON N/A
- CVKD N/A
- Industry
- RCON Oilfield Services/Equipment
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- RCON Energy
- CVKD Health Care
- Exchange
- RCON Nasdaq
- CVKD Nasdaq
- Market Cap
- RCON N/A
- CVKD 31.5M
- IPO Year
- RCON 2009
- CVKD 2023
- Fundamental
- Price
- RCON $1.96
- CVKD $14.62
- Analyst Decision
- RCON
- CVKD Strong Buy
- Analyst Count
- RCON 0
- CVKD 1
- Target Price
- RCON N/A
- CVKD $32.00
- AVG Volume (30 Days)
- RCON 8.7K
- CVKD 28.0K
- Earning Date
- RCON 01-01-0001
- CVKD 05-08-2025
- Dividend Yield
- RCON N/A
- CVKD N/A
- EPS Growth
- RCON N/A
- CVKD N/A
- EPS
- RCON N/A
- CVKD N/A
- Revenue
- RCON $8,996,572.00
- CVKD N/A
- Revenue This Year
- RCON N/A
- CVKD N/A
- Revenue Next Year
- RCON $15.18
- CVKD N/A
- P/E Ratio
- RCON N/A
- CVKD N/A
- Revenue Growth
- RCON N/A
- CVKD N/A
- 52 Week Low
- RCON $1.26
- CVKD $5.40
- 52 Week High
- RCON $3.70
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- RCON 64.44
- CVKD 29.15
- Support Level
- RCON $1.80
- CVKD $14.05
- Resistance Level
- RCON $1.98
- CVKD $16.28
- Average True Range (ATR)
- RCON 0.16
- CVKD 1.35
- MACD
- RCON 0.06
- CVKD -0.47
- Stochastic Oscillator
- RCON 96.55
- CVKD 9.60
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.